Ibnsina Pharma results, Q3 2026
Net profit, assets, equity and cash flow for Q3 2026, against the same period a year earlier, from the published financial statements. Consolidated figures cover the 9 months to 30 September 2026; the comparison is with the same months a year earlier, from the same disclosure.
In short
- Ibnsina Pharma's net profit for Q3 2026 was about 909 million EGP, up +37.7% from 660 million EGP in Q3 2025.
- Total assets at the end of Q3 2026 were about 44.69 billion EGP, and shareholders' equity about 3.38 billion EGP.
- Operating cash flow for Q3 2026 was positive at 877 million EGP.
Key lines against the same period a year earlier
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Consolidated figures cover the 9 months to 30 September 2026; the comparison is with the same months a year earlier, from the same disclosure.
Ibnsina Pharma's Fiscal year 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy